The arrival of GLP-1 receptor agonists and dual agonists has delivered unprecedented efficacy, reframed obesity as a chronic ...

Eli Lilly has halted a study of an experimental drug, designed to prevent obesity patients from losing too much muscle, due to strategic business reasons, according to a U.S. registry of clinical ...

New York City doctors reveals how weight-loss drugs reduce inflammatory cytokines by decreasing fat cells, potentially preventing cancer and autoimmune diseases.

Eli Lilly plans to launch its experimental oral weight-loss drug orforglipron in India, a senior executive said on Thursday, ...

Eli Lilly has halted a study of an experimental drug, which is designed to prevent obesity patients from losing too much ...

Eli Lilly plans to bring its experimental oral weight-loss drug orforglipron to India as it sees market potential in the ...

Oral Ozempic alternative Orforglipron inspired the biggest biotech investment in Texas history, in Generation Park.

Weight loss medications like Wegovy and Zepbound are gaining widespread attention for their dramatic results, and that demand ...

Pfizer is expediting its efforts to delve into the growing obesity treatment field with a nearly $5 billion acquisition. The ...

The multibillion-dollar investment will result in more than 600 permanent jobs, according to the company. The manufacturing ...

Eli Lilly said it plans to build a $6.5 billion facility in Houston to make active pharmaceutical ingredients, including for a new oral weight-loss drug. The plant will bring 615 jobs to the area, ...

“Eric’s experience bridging data science, digital health and patient care is exactly what Shotsy needs at this stage,” said Aja Beckett, founder of Shotsy. “His leadership will help ensure our ...